Development of an efficacious, non-addicting analgesic has been challenging. Discovery of novel mechanisms underlying addiction may present a solution. Here we target the neurokinin system, which is involved in both pain and addiction. Morphine exerts its rewarding actions, at least in part, by inhibiting GABAergic input onto substance P (SP) neurons in the ventral tegmental area (VTA), subsequently increasing SP release onto dopaminergic neurons. Genome editing of the neurokinin 1 receptor (NK 1 R) in the VTA renders morphine non-rewarding. Complementing our genetic approach, we demonstrate utility of a bivalent pharmacophore with dual activity as a μ/δ opioid agonist and NK 1 R antagonist in inhibiting nociception in an animal model of acute pain while lacking any positive reinforcement. These data indicate that dual targeting of the dopaminergic reward circuitry and pain pathways with a multifunctional opioid agonist-NK 1 R antagonist may be an efficacious strategy in developing future analgesics that lack abuse potential.
INTRODUCTION
The United States faces two simultaneous and associated epidemics. First, the widespread prevalence of pain over the past 20 years has led to the very well-publicized opioid epidemic. 1 Yet, 100 million Americans suffering from chronic pain still need efficacious analgesics, leaving the medical community in a conundrum. Although guidelines for prescribing opioids have been put forth by the Centers for Disease Control and Prevention, 2 it is likely that understanding how opioids drive reward pathways may lead to development of efficacious, non-addictive pain relievers.
Substance P (SP) has a storied role in propagating both the nociceptive and reward pathways in the peripheral and central nervous systems. 3 As an undecapeptide with principle biological activity at the neurokinin-1 receptor (NK 1 R), SP induces pronociceptive flinching and scratching behaviors when administered intrathecally (i.t.) 4 and elicits positive conditioned place preference (CPP) when administered into multiple central nervous system nuclei. 5 Therefore, the neurokinin system is a very attractive pharmacological target for both pain intervention and addiction. Although morphine can inhibit presynaptic SP release from dorsal root ganglia neurons in the spinal cord, 6 it also indirectly increases dopaminergic cell firing in the ventral tegmental area (VTA) of the midbrain by inhibiting tonically active, inhibitory GABAergic neurons. 7 Although NK 1 Rs are located in the VTA among other central nervous system regions, 8 and activation therein with SP elicits dopaminergic firing, 9 the role of SP in mediating the rewarding action of drugs of abuse is unclear.
Here we show that genomic editing of the NK 1 R, specifically in the VTA, of adult, male rats renders morphine non-rewarding. Additionally, we demonstrate that morphine exerts its rewarding actions, at least in part, by inhibiting GABAergic input onto SP neurons in the VTA, subsequently increasing SP release onto dopaminergic neurons. Finally, we demonstrate utility of a bivalent pharmacophore with dual activity as a μ/δ opioid agonist and NK 1 R antagonist in inhibiting nociception in an animal model of acute pain while lacking any positive reinforcement.
MATERIALS AND METHODS Animals
Male Sprague Dawley rats (250-300 g) and male ICR (20-25 g) mice purchased from Harlan (Indianapolis, IN, USA) were housed in a climate controlled room on a regular 12 h light/dark cycle with lights on at 0700 hours and food and water ad libitum. Rats were housed three per cage and used for all microdialysis, CPP and spinal nerve ligation (SNL) studies. Mice were housed five per cage and used for acute tail flick in a hot water bath and flinching studies. All procedures were performed during the 12-h light cycle and according to the policies and recommendations of the International Association for the Study of Pain, the NIH guidelines for laboratory animals, and were approved by the IACUC of the University of Arizona.
screwed in place to maintain guide cannula patency. The VTA microinjector guide cannula (22GA, 10 mm from pedestal, PlasticsOne, Roanoke, VA, USA) was lowered 7.5 mm through a hole drilled at P: 5.0 mm, L: 0.7 mm from the bregma. The NAc guide cannulas were fixed in place with dental cement, and all animals were given prophylactic subcutaneous antibiotic (gentamycin, 1 mg kg − 1 ). Rats were then allowed to recover for 3 days before undergoing microdialysis experiments.
Microdialysis for VTA and NAc sampling
Microdialysis experiments were performed 3 days after surgical implantation of the guide cannulas. For the VTA microdialysis experiments, the dummy probe was removed from the guide and a microdialysis probe (AZ-10-2, EiCom) was inserted and screwed into place. The probe was attached to a cannula swivel at the top of the cage to allow for real-time sampling in awake, freely moving rats. The microdialysis probe was perfused with artificial cerebral spinal fluid (NaCl 147 mM, KCl 2.8 mM, CaCl 2 1.2 mM, MgCl 2 1.2 mM) at a rate of 0.5 μl min − 1 . VTA dialysate was collected in microcentrifuge tubes containing 1 μl aprotinin (1 μM) placed in an automated, cooled, timed turnstile set to 1-h bins. Baseline (BL) microdialysis was run for 2 h before any pharmacological manipulations. Morphine (10 mg kg − 1 , intraperitoneal (i.p.)) or vehicle (saline, i.p.) were injected and four dialysate samples were collected over 4 h. After each hour, the microcentrifuge tubes were snap frozen in liquid nitrogen and subsequently stored at − 80°C until the dialysates were analyzed for SP content using a commercial SP ELISA (R&D Systems, Minneapolis, MN, USA).
For the NAc microdialysis experiments, the dummy probe was removed from the guide cannula and a microdialysis probe (AZ-8-2, EiCom) was inserted and screwed into place. Perfusing the probe at a rate of 2 μl min
, dialysate was collected in cooled microcentrifuge tubes in 30-min bins. BL microdialysis was run for 2 h before any pharmacological manipulations in the VTA. Drugs (morphine 5 μg, SP 1 μg, L-732,138 1 μg, TY032 2 μg or vehicle) were administered in 0.5-μl volumes over 50 s (0.01 μl s − 1 ) directly into the VTA via the surgically installed VTA guide cannula. Briefly, the dummy probe was removed at the time of drug administration and a prefilled 2-μl Hamilton syringe (Hamilton, Reno, NV, USA) was attached to the VTA guide cannula. Drugs were administered slowly to ensure minimal disruption of the VTA parenchyma. Dialysate was collected every 30 min for 3 h; cocaine 20 mg kg − 1 was then injected i.p. as a positive control for NAc extracellular DA content. Microcentrifuge tubes were stored in − 80°C until high-performance liquid chromatography analysis for DA content. NAc dialysate was analyzed using high-performance liquid chromatography (Agilent 1100, Agilent Technologies, Santa Clara, CA, USA; Coulochem III 5014B electrochemical detector, Thermo Fisher Scientific, Chelmsford, MA, USA).
Microdialysis probe verification
Following microdialysis experiments, animals were killed; brains were harvested and fixed in 4% paraformaldehyde. After cryoprotection in 30% sucrose, VTA/NAc blocks were sectioned in 40-μm increments on a cryostat (Microm HM 525, Thermo Scientific, Walldorf, Germany) and mounted. Slides were viewed microscopically (Olympus, Waltham, MA, USA) for visual identification of NAc and VTA cannula placements. Terminations of the guide cannulas were plotted on a rat brain atlas 10 for verification.
gRNA design for tachykinin receptor 1 (Tacr1) gene targeting
Our strategy was to target the Tacr1 gene using a gRNA designed to match the 5′ end of the protein sequence that is most likely to result in a complete loss of the protein. We identified and extracted the sequence of the Tacr1 gene from the genomic sequence of chromosome 4 from Sprague Dawley rats (AC_000072.1). To design the gRNA sequence, we screened for potential off-targets using the gRNA design tool (http://crispr. mit.edu). 11 No potential gRNA sequence met our criteria of selectivity in the first exon from the Tacr1 gene; thus the gRNA selected for knockout was located in exon 2 (on the reverse strand: GATGACCACTTTGGTAGCCG, score 89; Figure 3a) . As a control, we chose a gRNA targeting the same gene but in a non-coding region located in intron 1 of the Tacr1 gene (on the reverse strand: gTAAAATGGATATTTCGGTGC, score 89, a g was added at the 5′ end to ensure better expression downstream of the U6 promoter). 12 
Cloning of gRNAs
We used the pSpCas9(BB)-2A-GFP plasmid (PX458, Cat. no. 48138, Addgene, Cambridge, MA, USA), 13 which allows for simultaneous expression of the Cas9 enzyme with the gRNA and green fluorescent protein (GFP) to control for transfection efficiency. The plasmid was cut using BbsI restriction enzyme according to the manufacturer's instructions (Cat. no. FD1014; Thermo-Fisher Scientific, Waltham, MA, USA). The digested plasmid was extracted from a 1% agarose gel (Cat. no. K0691; Thermo-Fisher Scientific). Oligonucleotides were designed according to Ran et al. 13 for the cloning of either exon 2 targeting gRNA (Tacr1 forward: 5′-CACCGATGACCACTTTGGTAGCCG-3′; Tacr1 reverse: 5′-AAACCGGCTACC AAAGTGGTCATC-3′) or intron 1 targeting gRNA (Tacr1 control forward: 5′-CACCGTAAAATGGATATTTCGGTGC-3′; Tacr1 control reverse: 5′-AAACG CACCGAAATATCCATTTTAC-3′) and were obtained from Eurofins, Louisville, KY, USA. A 10 μM solution of forward and reverse oligonucleotides was annealed in a thermocycler using the following protocol: 37°C for 30 min, 95°C for 5 min, with a cooling to 25°C at a rate of 5°C min
. Then 100 ng of the digested pSpCas9(BB)-2A-GFP plasmid was set up for ligation with 50 nM of the annealed oligonucleotides at 22°C for 5 min using the Rapid DNA ligation Kit (Cat. no. K1422; Thermo-Fisher Scientific). The ligation products were transformed into Escherichia coli DH5α competent bacteria (Cat. no. C2987; New England Biolabs, Ipswich, MA, USA) according to the manufacturer's instructions. The integrity of all plasmids was confirmed by Sanger sequencing (Eurofins), and 100% efficiency was observed for the insertion of gRNA sequences into the pSpCas9(BB)-2A-GFP plasmid. Plasmids were purified from DH5α E. coli using the NucleoBond Xtra Maxi Kit (Cat. no. 740414, Macherey-Nagel, Düren, Germany).
In vivo transfection of clustered regularly interspaced short palindromic repeats (CRISPR) plasmids For in vivo transfection, the plasmids pSpCas9(BB)-2A-GFP-Tacr1-gRNA or pSpCas9(BB)-2A-GFP-Tacr1-control-gRNA were diluted to 0.5 μg μl − 1 in a 5% sterile glucose solution. Then Turbofect in vivo transfection reagent (Cat. no. R0541, Thermo-Fisher Scientific) was added following the manufacturer's instructions. Finally, 0.5 μl of the plasmid complexes were injected bilaterally into the VTA of Sprague Dawley rats.
CRISPR-Cas9 to knockdown the NK 1 R in the VTA Rats were anesthetized with 5% isoflurane in O 2 (2.5 l min − 1 ) and maintained at 2.5% isoflurane while fixed in a stereotaxic frame. Animals were microinjected with NK 1 R gRNA/Cas9 or control directly into the VTA bilaterally, but on each side individually, for a total volume of 0.5 μl over 5 min per side. The cannula was slowly removed and the skull burr hole was filled with bone wax (Medline Industries, Mundelein, IL, USA); animals were given prophylactic subcutaneous antibiotic (gentamycin, 1 mg kg − 1 ) and were used for microdialysis, CPP or immunohistochemical studies 3 weeks later.
CPP to morphine
Three weeks post-VTA Cas9 injections, animals' BLs were obtained in a modified, three chambered, rat-CPP/aversion (CPP/CPA) apparatus (San Diego Instruments, San Diego, CA, USA) as previously reported: 14 (1) an end chamber with rough floor and horizontal black/white striped walls; (2) an end chamber with smooth floor and solid black walls; and (3) a center chamber with solid gray walls and metal rod flooring. Rats were placed in the center chamber and a 15-min recording period indicated entrance into chambers and time spent in chambers. Any rat with 480% preference to any chamber during BL was excluded from the study. The rats were subdivided into morphine (10 mg kg Following CPP experiments, rats were killed via transcardial perfusion with 0.1 M phosphate buffer (PB) and 4% paraformaldehyde for tissue fixing. Next, the brains were removed; the VTA was blocked and placed in 4% paraformaldehyde for 30 min followed by 30% sucrose in 0.1 M PB for 2 days or until the specimen sunk. The VTA was sliced in coronal, 40-μm-thick sections and placed in cooled 0.1 M PB in a 12-well plate. The sections were placed in 1% sodium borohydride for 30 min followed by a copious rinse with 0.1 M PB 3 × 10 min. Sections were then rinsed in 0.1 M Tris saline 2 × 5 min followed by an incubation in 0.5% bovine serum albumin in Tris saline for 30 min for blocking. Tissue specimens were transferred to scintillation vials with a fine brush and incubated in anti-NK 1 R primary antibody (1:5,000; RA25001, Neuromics, Edina, MN, USA) in 0.1% bovine serum albumin/0.25% Triton in Tris saline for 2 days at 4°C. Following incubation, tissue was transferred to a 12-well plate with fine brush and rinsed with 0.1 M Tris saline 3 × 10 min. The slices were then incubated and light protected in anti-rabbit secondary antibody (Alexa-Flour goat anti-rabbit, 1:800, Thermo-Fischer Scientific) in 0.1% bovine serum albumin/0.1 M Tris saline for 2 h at room temperature. With continued protection from light, the tissue was rinsed in 0.1 M Tris saline 3 × 10 min and then 0.1 M PB 3 × 10 min. The tissue was mounted onto slides in 0.05 M PB and cover-slipped with Prolong Gold Antifade w/4, 6-diamidino-2-phenylindole (Thermo-Fischer Scientific). Images were viewed on a Olympus microscope and merged.
Acute thermal nociception in mice
Warm water bath (52°C) was used as a nociceptive stimulus to assay acute thermal nociception in mice. The thermal tail withdrawal latency was defined as the time (s) from immersion of two-thirds distal portion of the tail in water to its withdrawal. BL values for all animals were obtained prior to drug administration; animals were excluded if their tail withdrawal latency was 47 s at BL. Administration of compounds in mice were performed via i.t. injection using a slightly modified Hylden and Wilcox technique.
4,15 A 10 μl Hamilton syringe fitted with a 30-guage needle was used to administer 5 μl. Tail-flick times were then measured every 20 min for 2 h. A cutoff latency of 10 s was implemented to prevent tissue damage to the distal third of the tail.
Maximal percentage of efficacy was calculated and expressed as:
Acute thermal nociception in rats
Rats were assessed for thermal nociception using a modified method developed by Hargreaves et al. 16 Animals were allowed to acclimate for 30 min in a Plexiglas enclosure (Hargreaves Apparatus, Ugo Basile, Comerio, Italy) fixed on a clear glass plate. A mobile radiant infrared (IR) heat source was focused onto the left hindpaw from underneath the glass plate. A standard IR intensity was used for all animals and an automatic cutoff point of 32.4 s was set to prevent tissue damage. The heat source and timer were activated simultaneously by the experimenter and cutoff by a motion detector on the apparatus focused directly on the plantar surface of the left hindpaw. BL was assessed prior to i.t. compound administration. Paw withdrawal latency (PWL) values were collected every 15 min for 2.5 h after i.t. compound administration. PWL values were converted to percentage of antinociception.
SP-induced nocifensive behaviors in mice SP i.t. elicits nocifensive behaviors such as flinching as previously described. 17 We injected mice with TY032 (3 μg per 5 μl) and SP (0.3 μg per 5 μl) via lumbar puncture and observed flinching behavior for 5 min to determine whether the NK 1 antagonist blocked these elicited behaviors. Naloxone (1 mg kg − 1 , i.p.) or vehicle was injected 15 min prior to TY032 or vehicle to remove opioid activity, 18 which was subsequently injected 5 min prior to SP administration.
Lumbar i.t. catheter implant surgery for spinal drug delivery in rats
Male Sprague-Dawley rats were prepared with i.t. catheters as described by Yaksh and Rudy 19 for direct central drug administration. Rats were anesthetized with 80% ketamine/20% xylazine (1 mg kg
, i.p.) and placed in a stereotaxic frame (Stoelting). The cisterna magna was opened and a 7.5-cm catheter (PE10) was implanted in the spinal column, terminating in the lumbar region. The catheter was sewn into the cervical muscle to maintain its position and animals were given prophylactic subcutaneous antibiotic (gentamycin, 1 mg kg − 1 ). The rats were allowed to recover for 7 days before SNL surgeries. Animals exhibiting paralysis were excluded from further surgeries or testing.
SNL for induction of neuropathic pain in rats SNL was utilized to induce neuropathic pain as described by Kim and Chung. 20 Animals were anesthetized with 5% isoflurane in O 2 (2.5 l min − 1 ) and subsequently maintained with 2.5% isoflurane. The left lumbar/sacral region of the dorsal vertebral column was exposed and the left L 6 vertebra was removed. Both L 5 and L 6 nerves were individually ligated with 4-0 suture silk. The incision was closed and the animals were allowed to recover for 7 days. Animals exhibiting motor deficiencies or a lack of tactile allodynia were excluded from further testing. Sham control animals underwent the same procedures excluding the ligation of the L 5 /L 6 nerves.
Thermal hypersensitivity
Rats were assessed for thermal hypersensitivity using a modified method developed by Hargreaves et al. 16 Animals were allowed to acclimate for 30 min in a Plexiglas enclosure fixed on a clear glass plate. A mobile radiant IR heat source was focused onto the left hindpaw from underneath the glass plate. A standard IR intensity was used for all animals and an automatic cutoff point of 32.4 s was set to prevent tissue damage. The heat source and timer were activated simultaneously by the experimenter and cutoff by a motion detector on the apparatus focused directly on the plantar surface of the left hindpaw. Preinjury was assessed prior to SNL; postinjury BL was assessed prior to i.t. drug administration. PWL values were collected every 20 min for 3 h after i.t. drug administration.
Mechanical allodynia
Rats were assessed for mechanical allodynia 1 week after SNL-induced neuropathic pain using calibrated von Frey filaments (0.4-15.0 g). First, rats were allowed to acclimate in suspended wire-mesh cages for 30 min. Then von Frey filaments were used to probe perpendicularly the plantar surface of the left hindpaw. A response was elicited when the animal retracted the hindpaw from the wire-mesh floor. Preinjury values were assessed prior to SNL; postinjury BL was assessed prior to i.t. drug administration via the surgically installed i.t. catheter. von Frey filament probing was repeated every 20 min for 3 h after i.t. administration.
Rotarod motor impairment
Male Sprague-Dawley rats were trained to walk on a spinning rotarod device (Columbus Instruments International, Columbus, OH, USA) as described by Vanderah et al. 21 until all animals were able to remain on the rotating platform for 180 s at a speed of 10 revolutions per min. Following i.t. administration of TY032 or vehicle via the surgically installed i.t. catheter, the length of time the rats were able to remain on the device without falling was recorded at 20-min intervals for 120 min.
Statistical analyses
Microdialysis time courses were analyzed by nonparametric two-way analysis of variance (ANOVA; with multiple comparisons, post hoc StudentNewman-Keuls) with the area under the curve (AUC) analyzed with oneway ANOVA and Student's t-test when appropriate. CPP and flinching studies were analyzed by one-way ANOVA. Nociception time courses were analyzed by two-way ANOVA. Data were plotted in GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA) and represent the mean ± s.e.m. with statistical significance represented by Po0.05. Blinding was used for receptor density and nociception assays. No randomization was used. Predetermined sample size was based on our previous publications and literature review. 22, 23 The variance was similar in the groups being compared. − 1 (n = 16) significantly increases SP release (+36.8 ± 8.4%) in the VTA compared with vehicle-treated animals (n = 11, -6.2 ± 9.1%) 1 h postadministration and continues to significantly increase SP release in the VTA after 2 h of administration. Morphine in the presence of Muscimol (10 μM intra-VTA given after the first hour of dialysate collection, n = 6) had significantly reduced SP release (16.1 ± 19.4%) compared with morphine-onlytreated animals (72.0 ± 14.2%) at the 2-h time point. (e) Anatomical verification of microdialysis guide cannula placements from studies carried out in panel (d). (f) Intra-VTA administration of bicuculline 10 μM (n = 9) significantly increases SP release (+99.3 ± 23.3%) in the VTA during the first hour postadministration compared with vehicle-treated animals (n = 8, − 19.9 ± 3.2%). (g) Anatomical verification of microdialysis guide cannula placements from studies carried out in panel (f). *P o0.05, **P o0.005, ****P o0.0001; analyses based on experimental vs vehicle groups, two-way analysis of variance.
RESULTS
Systemic morphine acutely increases intra-VTA SP release via disinhibition of GABAergic neurons To examine the role SP has in opiate activation of the reward circuit, we employed microdialysis in the VTA of male Sprague Dawley rats (Figure 1a) . I.p. administration of morphine sulfate (10 mg kg − 1 ) significantly increased VTA SP release in the first hour compared with vehicle (+76.1 ± 42.9% of BL, n = 7, vs +5.3 ± 12.4% of BL, n = 10, respectively; Po0.005; Figure 1b) . SP release returned to BL following the first hour of increased release in the morphine-treated animals. To assess morphine's direct effect on SP release in the VTA, we administered morphine (35 mM) into the VTA via reverse microdialysis and analyzed the dialysate for SP release. Intra-VTA administration of morphine significantly increased VTA SP release in the first hour compared with vehicle (+36.8 ± 8.4% of BL, n = 16, vs − 6.2 ± 9.1% of BL, n = 11, respectively; Po0.05; Figure 1d ). Morphine administration into the VTA via reverse microdialysis continued to significantly increase SP release in the VTA compared with vehicle in the second hour (+72.0 ± 14.2% vs +8.7 ± 13.1%, respectively; Po0.005). After the morphine-induced increase at 1 h of SP release, a second set of animals received the GABA-A agonist muscimol (10 μM) 24 via the VTA microdialysis probe; in these animals, there was a significant attenuation of morphine-induced SP release by 2 h as compared with morphine-only-treated animals (16.1 ± 19.4% vs 72.0 ± 14.2%, respectively; Po0.01) (Figure 1d) .
It is established that morphine inhibits the firing of GABAergic neurons in the VTA, preventing the release of the inhibitory neurotransmitter gamma aminobutyric acid (GABA) onto 2 vs − 49.9 ± 37.6, respectively), which was reversed by co-administration of L-732,138. Intra-VTA morphine administration significantly increased AUC compared with vehicle (326.1 ± 111.1 vs − 72.7 ± 32.3, respectively), which was reversed by co-administration of L-732,138. *P o0.05, **P o0.01, ***P o0.005, #P o0.05. Two-way analysis of variance (ANOVA) employed to compare experimental vs vehicle in time courses, one-way ANOVA for AUC statistical analyses.
dopaminergic neurons. 7 As such, opioid-mediated disinhibition has been recognized as the primary mechanism of DA firing in the VTA. To test the hypothesis that GABAergic tone additionally inhibits SP firing and subsequent release, we administered the GABA-A receptor antagonist bicuculline (10 μM) directly into the VTA via reverse microdialysis and sampled the dialysate for SP release. During the first hour of VTA administration of bicuculline (n = 9), SP release was significantly increased to +99.3 ± 23.3% of BL compared with vehicle-treated animals (−19.9 ± 3.2% of BL, n = 8; P o0.0001; Figure 1f animals verified to have the guide cannula correctly positioned in the VTA were used in the analyses (Figures 1c, e and g ).
Intra-VTA administration of NK 1 antagonist blocks morphineinduced DA release in the NAc Following the studies investigating how morphine impacts SP release in the VTA, we sought to determine how SP in the VTA affects NAc DA release in vivo using microdialysis (Figure 2a) . Intra-VTA administration of SP (1 μg per 0.5 μl (n = 9)) significantly increased NAc DA release, peaking at 90 min postinjection (+103.6 ± 33.1%), compared with vehicle-treated animals (n = 7, P o0.05; Figure 2b ), and this was blocked by co-administration of the NK 1 R antagonist L-732,138 (1 μg per 0.5 μl). Intra-VTA administration of morphine (5 μg per 0.5 μl, n = 9) significantly increased NAc DA release, peaking at 30 min postinjection (+81.5 ± 26.8%), compared with vehicle-treated animals (n = 7, P o0.05; Figure 2c ). To determine whether the NK 1 R antagonist could attenuate intra-VTA morphine-induced DA release, we administered the NK 1 R antagonist L-732,138 (1 μg per 0.5 μl) in conjunction with morphine (5 μg per 0.5 μl, n = 8) directly into the VTA and measured DA release in the NAc. The combination did not significantly increase DA release compared with vehicletreated animals (n = 7; Figure 2c ). For comparison among groups, the AUC for percentage of change in DA release was calculated (Figure 2d ). SP and morphine were each significantly greater than their respective vehicle controls (402.60 ± 124.20 vs − 49.9 ± 37.6, and 326.1 ± 111.1 vs − 72.6 ± 32.3, respectively). Both SP-and morphine-induced DA release was blocked by co-administration with L-732,138. Only animals with proper VTA microinjections and NAc microdialysis guide cannula placements were included in data analyses ( Supplementary Figures S1a and b) .
CRISPR-Cas9 knockout of NK 1 R in the VTA prevents morphine CPP We next investigated whether selectively knocking out Tacr1, the gene encoding NK 1 R, specifically in the VTA of male SpragueDawley rats would block CPP to morphine. We injected CRISPRassociated protein-9 nuclease (Cas9) plasmids bilaterally into the VTA with the gRNA targeting either exon 2 (that is, NK 1 R KO) or intron 1 (that is, control CRISPR) of the Tacr1 gene (Figure 3a) . After 3 weeks, NK 1 R densities in the VTA were compared between KO and control animals using immunohistochemistry (Figure 3b) . Control animals displayed a NK 1 R density of 2.7 ± 0.7 while KO animals had significantly decreased receptor densities (0.8 ± 0.2, P o0.05; Figure 3c ). Three weeks after CRISPR-Cas9 plasmid injections, we began a training paradigm for morphine (10 mg kg − 1 ) and assessed the animals' CPP after 10 days. CRISPR-Cas9 control animals trained with morphine (n = 18) had significantly elevated CPP scores compared with vehicle-treated animals (144.9 ± 50.2 and -13.5 ± 46.6, n = 11, respectively, P o0.05; Figure 3d ). VTA-NK 1 R KO animals (n = 16) exhibited no difference in CPP score to morphine compared with vehicletreated animals (n = 11, -25.6 ± 34.0 and -30.5 ± 46.6, respectively), while those trained with morphine were significantly different between CRISPR KO and CRISPR control groups (P o 0.01, Figure 3d ). To examine the chemical correlate of this reward signature of NK 1 R KO animals, microdialysis was performed in the NAc after systemic administration of morphine or vehicle in NK 1 R CRISPR KO and control animals. The time course of DA release was evaluated and converted to AUC values. In CRISPR-Cas9 control animals, morphine (10 mg kg − 1 i.p.) significantly increased DA release in the NAc during the 3-h time course (n = 9, 380.4 ± 149.5) compared with vehicle (n = 8, 40.6 ± 51.3; P o 0.05; Figure 3e ). Among the CRISPR KO groups, morphine treatment did not significantly increase DA release in the NAc compared with vehicle treatment (98.0 ± 95.2, n = 7 and -89.8 ± 48.4, n = 8, respectively). For 55 days post-CRISPR-Cas9 injection, both NK 1 R KO and control animals gained body weight at the same rate (Figure 3f) , indicating that the reward processing for food intake/appetite was still intact while the reward processing of opioids was rendered nonfunctional.
TY032 results in antinociception in naive animals and in a model of neuropathic pain TY032, a μ/δ-opioid agonist and NK 1 R antagonist was designed to inhibit neuropathic pain while reducing both opioid dose escalation and unwanted side effects. 25 To determine the functional pharmacological properties of TY032, we investigated the compound's ability to inhibit SP-induced flinching in mice. SP (0.3 μg per 5 μl; n = 7) significantly increased flinching and scratching to 19.4 ± 3.5 in 5 min compared with vehicle (n = 7, 1.1 ± 0.5 in 5 min, P o0.005; Figure 4a ). I.t. TY032 3 μg per 5 μl (n = 6) significantly reduced SP-induced flinching to 2.8 ± 1.3 in 5 min (P o0.05). Additionally, with pretreatment of naloxone 1 mg kg − 1 , TY032 (n = 7) significantly reduced SP-induced flinching and scratching to 4.9 ± 1.8 in 5 min (P o0.05). With naloxone already on board, this suggests that TY032 is inhibiting SP-induced flinching primarily through its actions at the NK 1 R and not by way of its opioidergic activity.
To assess the opioidergic activity of TY032 in vivo, we performed a tail flick assay in a hot water bath (52°C) with mice and evaluated the degree to which naloxone inhibits the precipitated antinociception of TY032. TY032 (3 μg per 5 μl, i.t., n = 5) significantly increased tail withdrawal latency to 7.72 ± 1.33 s 40 min postinjection, compared with vehicle-treated animals (n = 7, 2.70 ± 0.40 s, P o 0.0005; Figure 4b ). Pretreatment with Control CRISPR animals trained with morphine exhibited significantly increased preference compared with vehicle-treated animals (n = 18, +144.9 ± 50.2 and n = 11, − 13.5 ± 46.6, respectively). VTA-NK 1 R KO animals trained with morphine (n = 16, − 25.6 ± 34.0) exhibited no significant difference from vehicle-treated animals (n = 11, − 30.5 ± 46.6). Within the groups trained with morphine, the CRISPR KO produced significantly reduced preference than the control CRISPR group. (e) Control CRISPR animals treated with morphine (10 mg kg − 1 intraperitoneal) had significantly increased dopamine (DA) release in the nucleus accumbens (NAc) (n = 9, AUC: 380.4 ± 149.5) compared with vehicle (n = 8, 40.61 ± 51.27). Within CRISPR KO groups, morphine treatment did not significantly increase DA release in the NAc compared with vehicle treatment (98.0 ± 98.0, n = 7 and − 89.8 ± 48.4, n = 8, respectively). (f) Animals gained weight at the same rate over the course of 55 days following VTA CRISPR administration. *P o0.05, **Po 0.01; Student's t-test used for NK 1 R density, one-way analysis of variance employed for CPP, AUC of DA release and body mass comparisons.
naloxone (1 mg kg − 1 , i.p., n = 7) reduced TY032 antinociception by about 50% but was not significantly different from vehicle-treated animals. TY032 (10 mg kg − 1 , i.p., n = 6) significantly increased hindpaw withdrawal latencies 15 min postinjection to +55.0 ± 13.0% of BL compared with vehicle-treated animals (n = 6, +16.9 ± 10.5% of BL, P o0.005; Figure 4c ). Percentage of antinociception remained significantly elevated compared with vehicle 2 h postinjection (P o0.05) and returned to BL by 2.5 h.
We next assessed whether TY032 was efficacious in reversing neuropathic pain in rats with SNL-a surgical model of neuropathic pain. We evaluated preinjury BL to innocuous mechanical stimuli with von Frey filaments and to thermal nociception with , i.p.; n = 13) produced a significantly positive CPP score of 128.0 ± 41.8 compared with vehicle-treated animals (n = 15). TY032 10 mg kg − 1 i.p. (n = 14) did not significantly increase CPP score compared with vehicle (1.1 ± 49.1 and − 13.9 ± 38.4, respectively). *Po 0.05, **P o0.01, ***P o0.005, ****Po0.001; one-way analysis of variance (ANOVA) used for SP-induced flinching, AUC of DA release and CPP studies. Two-way ANOVA employed for antinociception time courses with more than two groups.
the IR radiant heat source as described above, followed by SNL and a re-evaluation of mechanical and thermal thresholds 1 week later. To mechanical stimuli, animals were reliably neuropathic with a postinjury BL paw withdrawal threshold of 2.1 ± 0.6 g. TY032 (0.3 μg per 5 μl, i.t., n = 11) produced a significant antiallodynia compared with vehicle, peaking at 80 min postadministration (9.7 ± 1.8 g) and returning to BL after 180 min (Figure 4d ). We administered two additional doses of TY032 (0.1 and 0.2 μg per 5 μl) and constructed a dose-response curve for its effect on reversing mechanical allodynia. The A 50 was calculated to be 0.17 μg per 5 μl. Exposure to a thermal stimulus produced a postinjury BL PWL of 8.6 ± 0.8 s. TY032 (1.0 μg per 5 μl, i.t., n = 7) produced a significant antihyperalgesia compared with vehicle peaking 20 min postadministration (22.4 ± 3.2 s) and lasting 80 min (Figure 4e ). Two additional doses of TY032 were administered (0.1 and 0.3 μg per 5 μl) and a dose-response curve was constructed for its antihyperalgesic effect to thermal stimuli; the A 50 was calculated to be 0.12 μg per 5 μl.
To assess whether TY032 induces motor impairment, we used the rotarod test to evaluate the latency with which rats will maintain their walk on a rotating cylinder. TY032 (1 μg per 5 μl i.t., n = 6) did not significantly alter the latency to fall of the rod compared with vehicle-treated animals (n = 8, Supplementary Figure S2 ).
TY032 neither results in elevated levels of NAc DA release nor in CPP With TY032 demonstrating antinociceptive efficacy in mice and rats, we next investigated whether it has the potential for abuse. We first assessed the DAergic response to intra-VTA TY032 via microdialysis in the NAc and converted to AUC. TY032 (2.0 μg per 0.5 μl, n = 6) did not significantly change DA release compared with vehicle (n = 7) treated animals ( Figure 4f ). We next used the CPP paradigm described above wherein we trained male SpragueDawley rats with TY032 10 mg kg − 1 , i.p./once per day. After 10 days, we assessed their preference for morphine and TY032. The vehicle for morphine was saline while the vehicle used for TY032 was 10% DMSO, 10% Tween and 80% saline. Saline training produced a CPP score of 4.1 ± 40.6 (n = 15) while the positive control morphine (10 mg kg − 1 , i.p., n = 13) produced a significantly increased CPP score of 128.0 ± 41.8 (P o0.05; Figure 4g ). The vehicle for TY032 produced a CPP score of − 13.9 ± 38.4 (n = 13) while TY032 10 mg kg − 1 (n = 14) did not produce a statistically significant difference in CPP score (1.1 ± 49.1) compared with vehicle. These data indicate that while TY032 does produce antinociception when administered both centrally and systemically, it does not produce characteristics of reward.
DISCUSSION
Chronic pain affects 100 million Americans or 30% of the US population. 26 About 2.5 million Americans suffer from opioid abuse 27 due to prescription narcotics or heroin, placing researchers at an interesting crossroads of the two epidemics. 28 It is the view of many that the health profession is responsible for the opioid epidemic we face, and as such, it is the responsibility of the health profession to confront it. Deciphering possible dual acting mechanisms of inhibiting narcotic reward activation while enhancing pain relief may lead to the development of novel, non-addictive pain therapies.
Here we show the role SP has in mediating opioid activation of the reward pathway. Mu opioid agonists inhibit GABAergic input directly onto DA neurons 7, 29 (the canonical model); yet we demonstrate that they also relieve tonic inhibition of SP-containing neurons that promote dopamine (DA) firing, as evidenced by the bicuculline administration-induced SP release in the VTA and the SP-induced increase in DA release in the NAc. Studies have shown that the VTA is a highly heterogeneous brain region, containing DA, GABA and glutamate neurons. [30] [31] [32] GABAergic inputs from other areas of the central nervous system make connections onto non-dopaminergic neurons of the VTA and are sensitive to mu opioids. 33 Interestingly, a few reports suggest that mu opioid agonist DAMGO may directly stimulate some DA neurons of the VTA. 34 The activity of the DA cells in the VTA is also driven by glutamate. 35 SP is often contained in glutamatergic neurons and adds to the excitability of the postsynaptic neuron via neurokinin receptors (Gα q -protein coupled receptors). 36 This glutamate SP is found in primary nociceptive fibers to drive the spinal pain signal, 37 as well as in the rostral ventromedial medulla where activation of NK 1 Rs enhances responses of neurons evoked by N-methyl-D-aspartate, suggesting an ensuing sensitization. 38 There is strong evidence that a similar system may drive activation of DA neurons in the VTA. 39, 40 We provide compelling evidence that SP is, at the very least, a co-driver of DA neurons. Yet, the inability to block glutamate receptors to inhibit chronic pain or opioid-induced rewarding activity is encumbered with severe side effects of glutamate inhibition. A study by Ren and colleagues demonstrated that SP has the ability to evoke a 'slow' excitation in the DA cells of the VTA that can be blocked by an NK 1 R antagonist. 41 Studies using KO mice identified the NALCN (neuronal cation channel carrying a small background leak Na + current) as the cation channel activated by SP in the VTA. Most importantly, studies demonstrated that SP could drive action potentials of the DA cells of the VTA in neurons dissociated from wild-type mice but not from Nalcn − / − mice. 41 Using VTA-microdialysis, we now show that morphine-induced release of SP can be significantly attenuated by adding a GABA-A agonist, muscimol, demonstrating the disinhibition of SP release by morphine. Opiates such as morphine inhibit GABAergic neurons, thus preventing the release of GABA onto DA neurons. This disinhibition allows DA cells to fire and release their contents into the NAc, which relays positive reinforcement. We hypothesize that GABAergic neurons also maintain inhibitory control over substance P (SP) cells (green). When morphine inhibits GABAergic neurons, SPergic neurons fire and release their contents onto DA cells, acting as a 'driver' of DA function.
The link between SP neurons and their cognate receptor in the reward pathway has been established. 38, 39 Global NK 1 R − / − mice exhibited a lack of CPP 42 and self-administration 43 to morphine but not to cocaine, indicating a crucial role for the neurokinin system in mediating the reward to opiates and their mechanism of action in the VTA. Yet, a global deletion of the NK 1 R might suggest compensatory loss of an indirect mechanism that may result in the loss of the opioid rewarding behavior. Studies using a saporin toxin conjugated to SP administered into the amygdala of adult mice resulted in a similar reduction in opioid CPP behavior. 44 Hence, our studies help identify that SP and NK 1 Rs directly in the VTA are responsible for opioid-mediated increase in DA release into the NAc.
To the best of our knowledge, our study is the first to use a Cas9 approach to edit a gene in the adult rat brain to block a part of the reward pathway. Here we edited the NK 1 R in the VTA; these receptors localize to DA cells. 45 Removing the NK 1 R by CRISPRCas9 editing was sufficient to prevent DA release in the NAc in response to morphine. In addition, the CRISPR-Cas9 NK 1 R editing in rats resulted in the lack of a positive morphine-induced CPP. Yet, the selective NK 1 R CRISPR-Cas9-edited animals continued to gain weight normally over 2 months, much like naive or control animals, suggesting that their appetite drive was intact. These animals had no unusual behaviors and demonstrated no motor impairment when placed on a slow rotating rod. These studies strongly support the notion that NK 1 Rs in the VTA have a role in rewarding behavior and the idea that opioids can result in an increase in SP by inhibiting the release of GABA onto the SPcontaining neurons.
These findings along with our previous work in neuropathic pain 4, 14 supported the development of a novel multifunctional opioid that would act as an agonist at mu opioid receptors while inhibiting NK 1 Rs. TY032, a mu and delta opioid agonist/NK 1 antagonist, significantly attenuates behavioral signs of chronic neuropathic pain while not demonstrating rewarding behavior in a model of CPP. TY032 therefore represents the future of analgesics: multi-functional compounds designed to act at more than one molecular target to produce pain relief as well as endowed with properties to inhibit unwanted effects that so often limit dosing.
An unexpected finding from our microdialysis studies was the demonstration of a lack of a DA response to i.p. cocaine in CRISPR/ Cas9 NK 1 R KO mice or by NK 1 R antagonism in the VTA. Histological verification of surgical placements was evident, making the lack of DA in response to cocaine intriguing. This outcome contrasts with numerous studies, which suggest that only morphine, not cocaine, is rendered non-rewarding in whole-animal NK 1 R − / − and amygdaloid SP + neuron ablation. [42] [43] [44] Our finding might suggest that a lack of initial dopaminergic neuronal excitation is due to low NK 1 R availability and may result in alterations in the neuronal cation channel-carrying capacity as a background Na + leak current. Hence, cocaine has less DA for which to block reuptake in the NAc and therefore result in less DA that can be measured at the end of our microdialysis experiments. There is a precedent for other drugs of abuse, namely, alcohol, potentially being affected by NK 1 R antagonism, 46 making our unexpected finding all the more noteworthy and novel.
Our studies provide new insight into how opiates cause increases in DA in NAc and may heighten propensities toward addiction. Identifying SP as a common signaling factor in both pain and reward, we put forth the idea of rationally designing bifunctional drugs that target both the cellular pathology in chronic pain (that is, upregulated SP in nociceptors) and the cellular pathology of reward (that is, opioids in the VTA lead to the release of SP causing an increase in DA release in the NAc) for better analgesic efficacy while purposefully reducing unwanted side effects, such as addiction.
